The therapeutic benefits of combined sorafenib for intermediate stage hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population
from Journal of Digestive Diseases via Wiley Online Library
Transarterial chemoembolization (TACE) is the treatment modality to the intermediate stage, or BCLC stage B hepatocellular carcinoma (HCC), but the benefit to outcomes is still low. The aim of this study was to assess the outcomes of combined TACE and sorafenib to the patients with intermediate HCC.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063